Online inquiry

IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14487MR)

This product GTTS-WQ14487MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CNR1 gene. The antibody can be applied in Non-alcoholic fatty liver disease (NAFLD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001160226.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1268
UniProt ID P21554
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14487MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4105MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ11823MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-4280
GTTS-WQ3076MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ8078MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ13202MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15903MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ12013MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ4050MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW